10x Genomics Completes Largest Life Sciences IPO of 2019
09.20.19
This is only gets display when printing
Simpson Thacher advised 10x Genomics (Nasdaq: TXG) in its recent $448.5 million initial public offering of 11,500,000 shares of its Class A common stock, which includes the exercise in full of the underwriters’ option to purchase 1,500,000 additional shares of its Class A common stock, at a public offering price of $39 per share. The offering, which was upsized and priced above its increased range, is the largest life sciences IPO to date in 2019.
10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health. The company’s integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology.
The Simpson Thacher team included Kevin Kennedy, E. Ryan Coombs, Adam Spaulding and Mary Keating (Capital Markets); and Tristan Brown, Annie Kim and Erik Ward (Executive Compensation and Employee Benefits).